EP Patent

EP0398207A1 — Stable liquid form of 5-aminosalicylic acid

Assigned to Aventis Pharmaceuticals Inc · Expires 1990-11-22 · 35y expired

What this patent protects

An aqueous solution of 5-aminosalicylic acid (5-ASA) and a nontoxic alkali, alkali metal or alkaline earth metal salt of 5-aminosalicylic acid having a pH of 3-5 is dis­closed. The sole buffer in the solution is that intrinsic­ally formed by 5-aminosalicylic acid and its alkali, …

USPTO Abstract

An aqueous solution of 5-aminosalicylic acid (5-ASA) and a nontoxic alkali, alkali metal or alkaline earth metal salt of 5-aminosalicylic acid having a pH of 3-5 is dis­closed. The sole buffer in the solution is that intrinsic­ally formed by 5-aminosalicylic acid and its alkali, alkali metal or alkaline earth metal salt. The solutions prefer­ably also contain an antioxidant and a metal complexing agent. In preferred practice, the 5-ASA salt is formed in situ by addition of an alkali, alkali metal or alkaline earth metal hydroxide to a solution of 5-ASA. The solution is stable and does not significantly discolor due to 5-ASA decomposition for extended periods of time.

Drugs covered by this patent

Patent Metadata

Patent number
EP0398207A1
Jurisdiction
EP
Classification
—
Expires
1990-11-22
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.